Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.51

+2.7%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scott_jiminez who wrote (9947)	1/7/2004 11:02:28 AM
From: VIXandMore	Read Replies (1) of 52153

Thoughts on AXYX valuation? I'm curious if any of the resident gurus are willing to evaluate the prospects for AXYX and their potential in the Alzheimers market. This question partly triggered by today's runup and Sandler & Co., which "names Axonyx as their #1 idea going into next week's JP Morgan Healthcare conference (co presents on Jan 13), with a $15 target; firm is hearing that not only is the co's Phenserine (for Alzheimers) acting with the highest AChE specificity, but also acts as an APP inhibitor, and they believe that the drug may demonstrate an ability to stop or even reverse the process of Alzheimers, with a superior side effect profile. Also, firm would not be surprised if a major pharmaceutical commercial deal for Phenserine occurs in 1H04."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next